Sabutoclax (BI97C1) and BI112D1, putative inhibitors of MCL-1, induce mitochondrial fragmentation either upstream of or independent of apoptosis

Neoplasia (United States)

Volumn 15, Issue 5, 2013, Pages 568-578

  Varadarajan, Shankar ^a   Butterworth, Michael ^a   Wei, Jun ^b   Pellecchia, Maurizio ^b   Dinsdale, David ^a   Cohen, Gerald M ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BH3 PROTEIN; BL 112D1; BL 97C1; PROTEIN BAK; PROTEIN BAX; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; SABUTOCLAX; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 1,1',6,6',7,7'-HEXAHYDROXY-3,3'-DIMETHYL-N5-(2-PHENYLPROPYL)-N5'-(2-PHENYLPROPYL)-2,2'-BINAPHTHYL-5,5'-DICARBOXAMIDE; ADENOSINE TRIPHOSPHATE; ANILINE DERIVATIVE; BI112D1; DNM1L PROTEIN, HUMAN; GOSSYPOL; GUANOSINE TRIPHOSPHATASE; MCL1 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; MITOCHONDRIAL PROTEIN; MYELOID LEUKEMIA FACTOR 1; NAVITOCLAX; OPA1 PROTEIN, HUMAN; SULFONAMIDE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MITOCHONDRION; OPTIC NERVE ATROPHY; PRIORITY JOURNAL; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; METABOLISM; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE;

ADENOSINE TRIPHOSPHATE; ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; GOSSYPOL; GTP PHOSPHOHYDROLASES; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICROTUBULE-ASSOCIATED PROTEINS; MITOCHONDRIA; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL PROTEINS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; REACTIVE OXYGEN SPECIES; SULFONAMIDES;

EID: 84877047169     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13230     Document Type: Article

References (48)

1. Chipuk JE and Green DR (2008). How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol 18, 157-164.
2. Danial NN and Korsmeyer SJ (2004). Cell death: critical control points. Cell 116, 205-219.
3. Adams JM and Cory S (2007). The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26, 1324-1337.
4. Youle RJ and Strasser A (2008). The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9, 47-59.
5. Lessene G, Czabotar PE, and Colman PM (2008). BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 7, 989-1000.
6. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681.
7. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et al. (2008). ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68, 3421-3428.
8. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, et al. (2006). The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10, 389-399.
9. Vogler M, Dinsdale D, Dyer MJ, and Cohen GM (2009). Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 16, 360-367.
10. Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ, and Cohen GM (2009). Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 16, 1030-1039.
11. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al. (2010). The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905.
12. Dai Y and Grant S (2007). Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res 67, 2908-2911.
13. Gores GJ and Kaufmann SH (2012). Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev 26, 305-311.
14. Zhang H, Guttikonda S, Roberts L, Uziel T, Semizarov D, Elmore SW, Leverson JD, and Lam LT (2011). Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene 30, 1963-1968.
15. Warr MR and Shore GC (2008). Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med 8, 138-147.
16. Hardwick JM, Chen YB, and Jonas EA (2012). Multipolar functions of BCL-2 proteins link energetics to apoptosis. Trends Cell Biol 22, 318-328.
17. Hetz C and Glimcher L (2008). The daily job of night killers: alternative roles of the BCL-2 family in organelle physiology. Trends Cell Biol 18, 38-44.
18. Karbowski M, Norris KL, Cleland MM, Jeong SY, and Youle RJ (2006). Role of Bax and Bak in mitochondrial morphogenesis. Nature 443, 658-662.
19. Sheridan C, Delivani P, Cullen SP, and Martin SJ (2008). Bax- or Bak-induced mitochondrial fission can be uncoupled from cytochrome c release. Mol Cell 31, 570-585.
20. Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, Temirov J, Cleland MM, Pelletier S, Schuetz JD, et al. (2012). Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol 14, 575-583.
21. Wei J, Kitada S, Rega MF, Stebbins JL, Zhai D, Cellitti J, Yuan H, Emdadi A, Dahl R, Zhang Z, et al. (2009). Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 52, 4511-4523.
22. Wei J, Stebbins JL, Kitada S, Dash R, Placzek W, Rega MF, Wu B, Cellitti J, Zhai D, Yang L, et al. (2010). BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 53, 4166-4176.
23. Dash R, Azab B, Quinn BA, Shen X, Wang XY, Das SK, Rahmani M, Wei J, Hedvat M, Dent P, et al. (2011). Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci USA 108, 8785-8790.
24. Jackson RS II, Placzek W, Fernandez A, Ziaee S, Chu CY, Wei J, Stebbins J, Kitada S, Fritz G, Reed JC, et al. (2012). Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer. Neoplasia 14, 656-665.
25. Wei J, Kitada S, Stebbins JL, Placzek W, Zhai D, Wu B, Rega MF, Zhang Z, Cellitti J, Yang L, et al. (2010). Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/ leukemia-2 (Bcl-2) family proteins. J Med Chem 53, 8000-8011.
26. Wei J, Stebbins JL, Kitada S, Dash R, Zhai D, Placzek WJ, Wu B, Rega MF, Zhang Z, Barile E, et al. (2011). An optically pure apogossypolone derivative as potent pan-active inhibitor of anti-apoptotic bcl-2 family proteins. Front Oncol 1, 28.
27. Vogler M, Dinsdale D, Sun XM, Young KW, Butterworth M, Nicotera P, Dyer MJ, and Cohen GM (2008). A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ 15, 820-830.
28. Varadarajan S, Bampton ET, Smalley JL, Tanaka K, Caves RE, Butterworth M, Wei J, Pellecchia M, Mitcheson J, Gant TW, et al. (2012). A novel cellular stress response characterised by a rapid reorganisation of membranes of the endoplasmic reticulum. Cell Death Differ 19, 1896-1907.
29. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, et al. (2012). Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30, 488-496.
30. Hoppins S, Lackner L, and Nunnari J (2007). The machines that divide and fuse mitochondria. Annu Rev Biochem 76, 751-780.
31. Chen H and Chan DC (2005). Emerging functions of mammalian mitochondrial fusion and fission. Hum Mol Genet 14 Spec No. 2, R283-R289.
32. Westermann B (2008). Molecular machinery of mitochondrial fusion and fission. J Biol Chem 283, 13501-13505.
33. Berrieman HK, Smith L, O'Kane SL, Campbell A, Lind MJ, and Cawkwell L (2005). The expression of Bcl-2 family proteins differs between nonsmall cell lung carcinoma subtypes. Cancer 103, 1415-1419.
34. Borner MM, Brousset P, Pfanner-Meyer B, Bacchi M, Vonlanthen S, Hotz MA, Altermatt HJ, Schlaifer D, Reed JC, and Betticher DC (1999). Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer 79, 952-958.
35. Wesarg E, Hoffarth S, Wiewrodt R, Kroll M, Biesterfeld S, Huber C, and Schuler M (2007). Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer 121, 2387-2394.
36. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, Belec L, Billot X, et al. (2007). Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 104, 19512-19517.
37. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, and Cohen GM (2009). Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 113, 4403-4413.
38. Varadarajan S, Tanaka K, Smalley JL, Bampton ETW, Pellecchia M, Dinsdale D, Willars GB, and Cohen GM (2013). Endoplasmic reticulum membrane reorganization is regulated by ionic homeostasis. PLos One 8, e56603.
39. Cassidy-Stone A, Chipuk JE, Ingerman E, Song C, Yoo C, Kuwana T, Kurth MJ, Shaw JT, Hinshaw JE, Green DR, et al. (2008). Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev Cell 14, 193-204.
40. Frank S, Gaume B, Bergmann-Leitner ES, Leitner WW, Robert EG, Catez F, Smith CL, and Youle RJ (2001). The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev Cell 1, 515-525.
41. Ishihara N, Fujita Y, Oka T, and Mihara K (2006). Regulation of mitochondrial morphology through proteolytic cleavage of OPA1. EMBO J 25, 2966-2977.
42. Olichon A, Elachouri G, Baricault L, Delettre C, Belenguer P, and Lenaers G (2007). OPA1 alternate splicing uncouples an evolutionary conserved function in mitochondrial fusion from a vertebrate restricted function in apoptosis. Cell Death Differ 14, 682-692.
43. Ehses S, Raschke I, Mancuso G, Bernacchia A, Geimer S, Tondera D, Martinou JC, Westermann B, Rugarli EI, and Langer T (2009). Regulation of OPA1 processing and mitochondrial fusion by m-AAA protease isoenzymes and OMA1. J Cell Biol 187, 1023-1036.
44. Head B, Griparic L, Amiri M, Gandre-Babbe S, and van der Bliek AM (2009). Inducible proteolytic inactivation of OPA1 mediated by the OMA1 protease in mammalian cells. J Cell Biol 187, 959-966.
45. Quiros PM, Ramsay AJ, Sala D, Fernandez-Vizarra E, Rodriguez F, Peinado JR, Fernandez-Garcia MS, Vega JA, Enriquez JA, Zorzano A, et al. (2012). Loss of mitochondrial protease OMA1 alters processing of the GTPase OPA1 and causes obesity and defective thermogenesis in mice. EMBO J 31, 2117-2133.
46. Duvezin-Caubet S, Jagasia R, Wagener J, Hofmann S, Trifunovic A, Hansson A, Chomyn A, Bauer MF, Attardi G, Larsson NG, et al. (2006). Proteolytic processing of OPA1 links mitochondrial dysfunction to alterations in mitochondrial morphology. J Biol Chem 281, 37972-37979.
47. Youle RJ (2005). Morphology of mitochondria during apoptosis: worms-tobeetles in worms. Dev Cell 8, 298-299.
48. Vogler M, Furdas SD, Jung M, Kuwana T, Dyer MJ, and Cohen GM (2010). Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. Clin Cancer Res 16, 4217-4225.